SHARE

Porton Pharma Solutions Announces New Flagship Facility Offering Integrated API Crystallization And Drug Product Development Services Porton Pharma Solutions Announces New Flagship Facility Offering Integrated API Crystallization And Drug Product Development Services
13.09.2023

Porton Pharma Solutions Announces New Flagship Facility Offering Integrated API Crystallization And Drug Product Development Services

Porton Pharma Solutions Announces New Flagship Facility Offering Integrated API Crystallization And Drug Product Development Services

Porton Pharma Solutions has just opened its new drug development facility in Cranbury, New Jersey, operated under its US subsidiary J-Star Research. With over 40,000 square feet of floor space, this facility is customer built to provide world-leading services in API crystallization/isolation and drug product development from R&D to GMP delivery. It is adjacent to the existing API synthesis facility at the same Cranbury campus. This addition expands the CMC services offered by J-Star from API synthesis further into fully interactive drug substance and drug product (DS-DP) development.

Porton Pharma Solutions Announces New Flagship Facility Offering Integrated API Crystallization And Drug Product Development Services
Porton Pharma Solutions Announces New Flagship Facility Offering Integrated API Crystallization And Drug Product Development Services

In addition to three modular and flexible drug product GMP suites, also built in are a dedicated spray drying suite, and a Drug Product Intermediates (DPI) suite where our solvent based, unique techniques in the Co-processing Technology platform can improve API morphology or PSD and results in speedier, simpler, and more robust DP process development. The R&D labs are for Drug Product Development, Material Science (solid form screen & selection and pre-formulation evaluation), Crystallization Process Development, Continuous Processing and Potent Compound handling. These labs allow experimentation and delivery processing from sub-mg to multi-kg scale. All the labs and suites are equipped with comprehensive state-of-the-art instrumentation. The unique arrangement, with extensive material-science-based powder characterization and instrument scale-down capabilities also enables material sparing approach to formulation and DP process development.

“With the new drug development facility in New Jersey, we will be able to solve much more and broader challenging problems in support of fast-paced drug development programs. We have already demonstrated that our integrated DS-DP R&D approach effectively facilitates problem solving and speeds up the developmental works. The DP GMP suites and expanded R&D labs allow our services to benefit more drug development programs.” says Dr. Renee Miao, CEO of J-Star Research and Porton USA.

Porton Pharma Solutions Announces New Flagship Facility Offering Integrated API Crystallization And Drug Product Development Services

The facility's global reach is noteworthy too. In addition to the US establishment, Porton has a full range of DS and DP R&D and manufacturing facilities in China. For compounds moving into late phases or commercialization after early development in the US, tech-transfer support by Porton’s US-based experts to its manufacturing facilities in China offers clients a trusted global approach to drug development and manufacturing.

"Our new drug product facility represents a significant step forward in our mission to provide our clients with the best possible service and solutions. We are excited that our expansion will allow us to further work on projects solving technical challenges as a truly global partner in the pharmaceutical industry" - Oliver Ju, CEO of Porton Pharma Solutions.

Porton Pharma Solutions Announces New Flagship Facility Offering Integrated API Crystallization And Drug Product Development Services

About Porton Pharma Solutions

Porton Pharma Solutions is a leading contract development and manufacturing organization (CDMO) providing high-quality technical services to the pharmaceutical industry. With a focus on innovation, technical expertise, and problem-solving, Porton is committed to delivering cost-effective solutions to drug development programs. The company's services include drug substance development, analytical development, drug product development, and manufacturing. For more information, please visit www.portonpharma.com.

SHARE

Porton Pharma Solutions Announces New Flagship Facility Offering Integrated API Crystallization And Drug Product Development Services Porton Pharma Solutions Announces New Flagship Facility Offering Integrated API Crystallization And Drug Product Development Services
Porton Experts Invited To Participate In The University Of Perugia Master PRO-API Program, Aiding In The Training Of Green Process Chemistry Professionals Porton Will Be Participating In Biotech Outsourcing Strategies Events This June Proton At CPhI North America Again Porton 2023 ESG Report Upcoming Porton Shows In Europe And The USA:Shaping Our Future Together Porton Makes Debut At DCAT Week 2024 To Jointly Promote Industry Development Join Our Founder And CEO @ DCAT Week Porton Pharma Solutions Joined The SBTi To Drive Climate Action Farewell To 2023, And WE Are Sailing Forward To 2024 The Pharma Crystallization Summit (PCS) Is Held Annually To Bring Together Developers Of New Medicines With Crystallization Challenges And The Crystallization Experts (Solution Providers) In The Industry And Academia. Porton Gets Improved In The 2023 S&P Global ESG Score Porton Pharma Solutions Announces New Flagship Facility Offering Integrated API Crystallization And Drug Product Development Services Pharma Digital Intelligence Summit Will Be Held On 5th, September, 2023 [Important Notice] Porton Announcement Regarding The Change Of Email Domain Porton Unveils Its Small Molecule Platform Headquarters In Shanghai PORTON Starts Construction Of Its Facility For Antibodies And ADCs In Shanghai Porton At DCAT Week 2023: A Highly Successful And Strategic Event Porton Released 2022 CSR Report Porton Delivers Strong 2022 Performance With 127% Sales Growth Porton Gets Above-Average S&P Global Environmental, Social, And Governance (ESG) Score
News

Insights Unveiled: Delve into Our Global News Hub!

22.05.2024

Porton Pharma Solutions embark on the next frontier in Mengeš, Slovenia

  • Opening ceremony of the state-of-the-art research and development laboratories for active pharmaceutical ingredients, small molecules, of Porton in Mengeš

  • A donation of EUR 20,000.00 to the municipality of Mengeš for the restoration of a flooded kindergarten

  • New jobs and further growth in the field of API's small molecules in Slovenia, Mengeš

Read the news

Cookie settings

Your current status

Show details